Randomized trial · people
NMN raised serum nicotinamide over 12 weeks in middle-aged adults
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In healthy middle-aged adults, 12 weeks of NMN raised one NAD+-related blood marker without side effects, but it did not significantly change arterial stiffness.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 36
- Published
- 2023
- Journal
- Sci Rep
What they tested
The team tested whether taking NMN (nicotinamide mononucleotide, a building block the body uses to make NAD+) by mouth for 12 weeks changes NAD+ metabolism and other blood and health measures in healthy adults.
How the study was done
A randomized, double-blind, placebo-controlled trial in 36 healthy middle-aged adults. For 12 weeks, people took one capsule of either 125 mg NMN or a placebo (a dummy capsule) twice a day.

What they found
Of the NAD+-related compounds measured, serum nicotinamide was significantly higher in the NMN group than in the placebo group. Pulse wave velocity, a measure of arterial stiffness, trended lower with NMN, but the difference between the groups was not significant. The 250 mg/day intake was well tolerated, with no adverse events.
What it doesn’t show
This was a small, 12-week trial in healthy middle-aged people only, so it can't show effects in older or sick people or over longer periods. The arterial stiffness change did not reach significance, so it is not an established effect.
The paper
Katayoshi et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023.
The compounds
More studies on NAD+
- NAD+: NR and NMN, not nicotinamide, raised blood NAD+ in 14 daysRandomized trial · people · 2026
- NMN supplements raised blood NAD+ levels in healthy older menRandomized trial · people · 2022
- NMN raised muscle insulin sensitivity in women with prediabetesRandomized trial · people · 2021
- NAD+ rose with nicotinamide riboside in a 6-week crossover trialRandomized trial · people · 2018
- Every study on NAD+
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.